Abstract: This study evaluated the subchronic toxicity of StemEnhance™, an extract of the blue-green alga Aphanizomenon flos-aquae that is used as a health supplement. Groups of 12 rats of each sex were given either 5% glycerin in water (control) or 200 mg/kg of StemEnhance prepared in 5% glycerin in water for 90 days by oral gavage. The administration of StemEnhance had no effect on behavior, food and water intake, growth, or survival. Values at the end of dosing and observation periods did not reveal differences between treated and control groups for hematology and clinical chemistry. There were no significant differences in the gross and histopathology of the reproductive organs in either males or females. Sperm motility parameters were similar for control and treated males. Our results show that StemEnhance at doses ∼7 times the maximum label-recommended daily dose did not produce adverse effects in Wistar rats after subchronic treatment.
Introduction
Aphanizomenon flos-aquae (AFA) is a cyanobacterium ('blue-green algae', BGA) that grows worldwide. AFA is primarily harvested from Upper Klamath Lake in southern Oregon for use in nutraceuticals. AFA is a good source of dietary polyunsaturated fatty acids (PUFA). Dietary supplementation with 10% and 15% algae significantly decreased cholesterol and plasma triglyceride concentrations in rats. 1 Consumption of AFA (1.5 g) by 21 volunteers resulted in rapid changes in immune cell trafficking, but not direct activation of lymphocytes. That is, AFA increased immune surveillance without directly stimulating the immune system.
experimental design
The rats received a standard laboratory diet (Harlan 8604 rodent diet, Harlan Laboratories, Inc, Indianapolis, IN, USA) and tap water ad libitum. StemEnhance suspension was prepared as described in an earlier publication. 9 A constant volume of this suspension (100 mg/mL) (0.2 mL/100 g of body weight) was administered daily by oral gavage for 90 days. This dose is 7 times the maximum label-recommended daily dose for human consumption. The dose was given at a similar time each day and adjusted as necessary to maintain a constant dose level in terms of animal body weight. Control animals received an equal volume of water with 5% glycerin without StemEnhance using the same administration route. General clinical observations were made at least once a day, usually at the same time(s) each day. The health conditions of the animals were recorded. All animals were weighed once a week. Measurements of food and water consumptions were made at least weekly.
gross pathology
Gross pathology was performed by a veterinary pathologist as described in an earlier publication. 9 Briefly, all of the animals were submitted to full necropsy procedures, including examination of the following organs and/or sites: external surface of the body; all orifices; cranial cavity; cervical tissues and organs; thoracic cavity and its contents, organs, and tissues; and abdominal cavity and its contents, organs, and tissues. Wet weight was determined for the following organs: liver, brain, spinal cord, heart, kidneys, spleen, adrenals, testes, epididymides, uterus, and ovaries as described in an earlier publication. 9 Organ weights were expressed as absolute values (g) and as relative (organ to body weights) values (gram per 100 g of body weight).
histopathology
Full histopathology was carried out by a veterinary pathologist on all animals as described previously. 9 Briefly, harvested tissues were fixed in 10% neutral buffered formalin for a minimum of 48 h prior to trimming. Following fixation, tissues composed of bone were decalcified with a standard decalcifying solution (formic acid and sodium citrate). The fixed-decalcified tissues were exposed to routine processing, embedded in paraffin, and sectioned at 5 µm. Tissue sections were stained with hematoxylin and eosin using an automated staining system (Tissue Tek, Fisher Scientific, Waltham, MA, USA).
hematology and clinical biochemistry
Blood samples were collected from the lateral vein of rats before dosing commenced. Additionally, at the end of the dosing period, blood samples were collected during necropsy directly from the heart for hematology (EDTA-containing microtubes were used as an anticoagulant) and clinical biochemistry analysis. Clotted and hemolyzed samples were excluded from analysis. Standard serum chemistry and hematology profiles were determined. 9 The following hematological examinations were made: packed cell volume (PCV), hemoglobin concentration (Hb), erythrocyte count (RBC), total and differential leukocyte count (white blood cell (WBC)), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC). Additionally, the following clinical biochemical analyses of blood were carried out: glucose, calcium, phosphorus, creatinine, total protein, albumin, globulin, cholesterol, bicarbonate, anion gap, sodium, potassium, chloride, triglycerides, gamma-glutamyltransferase (GGT), epididymal sperm count, motility, and morphology At necropsy, the right cauda epididymis was immediately removed, weighed, and the tissue was processed. 9 Briefly, sperm counts were determined in six standard viewing fields and calculated per cauda and per gram of testis. A minimum of 200 sperms was analyzed per animal. The sperm motion parameters recorded were percentage of motile sperm, percentage of progressively motile sperm (progressive motility), average path velocity (VAP), straight line velocity (VSL), curvilinear velocity (VCL), amplitude of lateral head displacement (ALH) beat cross frequency, straightness (STR), and linearity (LIN). Percentage progressive sperm is the ratio of the number of motile sperm with path velocity (VAP) . V 0 and STR . S 0 to the total number of sperm. 13 For the sperm morphological analysis, 10 µL of the 1:9 diluted sperm from the motility analysis prepared as described previously 9 was pipetted on a pretreated glass microscope slide and spread with pipette tip to cover 1/2-2/3 of the slide. The slides were dried on a slide warmer at 37-40°C. The dried slides were placed in fixative (3 parts 100% ethanol and 1 part glacial acetic acid) for 2 min. The slides were drained and dried on a slide warmer. Fixed and dried sperm slides were placed in Coomassie Blue stain for 2.5 min and rinsed very quickly (one dip) in 70% ethanol and then 2 times in distilled water (3-4 dips in each rinse). The back of the slides was dried with tissue paper, followed by drying on a slide warmer at 37-40°C. Additional fixed and dried sperm slides were placed in Toluidine Blue stain (1% w/v in distilled water) for 15 min. The slides were rinsed 2 times in distilled water (3-4 dips in each rinse). The back of the slides was dried with tissue paper, followed by drying on a slide warmer at 37-40°C. A total of 200 sperms was analyzed morphologically under microscope for each control and treated males.
Statistical procedure
Statistical analysis was performed as described previously. 9 Briefly, means and standard deviations of means for groups, mean values of body weights, food and water consumption, absolute organ weights, relative organ weights, and hematological and biochemical parameters were calculated. Data were checked for normality using the Shapiro-Wilk and Anderson-Darling tests. Standard repeated analysis of variance was used for statistical evaluation of the data. When a significant effect was found, Tukey's multiple comparison and within-treatment contrast tests were used for further analysis. The statistical significance level was set at P # 0.05 (SYSTAT 13, Systat Inc, Chicago, IL, USA). Estimates of power were calculated using published control data for various organs and hematology in males and females and sperm velocity parameters. 14, 15 The assumptions were 80% power and α = 0.05 for a 10% and 20% two-sided treatment effect that shifted the mean but did not affect the variance.
Results

Death, abnormalities, and feeding
One female and male in the treatment group and one female in the control group died due to gavage complications, and they were excluded from histopathogical data. No other deaths or clinical abnormalities for any male or female animals were observed during the experimental period. There were no significant differences in mean body weight gains in treated females in comparison to the controls as a result of 200 mg/kg oral administration of StemEnhance (Figure 1) . Similarly, administration of StemEnhance did not cause any significant changes in weekly water and food consumption in treated females in comparison to controls (Figures 2 and 3 ). In males, there were no significant differences in mean body weight gain and in mean weekly water and food consumption between treated and control rats (Figures 4-6 ). Tables 1 and 2 show the absolute and relative organ weights in treated and control females and males, respectively. There was a 12% increase in the absolute (P = 0.056) and relative (P = 0.076) mean spleen weights for treatment versus control females. Relative epididymis weights (R + L) were increased 11.1% in treated males (P = 0.045). 
gross pathology
Week
Body weight (g) 8 There were no statistically significant differences in the relative or absolute weights of all other organs between treated and control groups in females or males. The increased spleen and epididymis weights were not connected with any pathological processes (per the histopathology) and therefore could not be linked with administration of StemEnhance.
Organ weights were also normalized to the brain. 16 Test materials that alter body weight generally do not alter brain weight, making organ-to-brain weight ratios useful in cases of notable decreases in body weight that impact organ-to-body weight ratios. 17 Organ-to-brain weight ratios also may be helpful in normalizing animal-to-animal variability. 18 There were no significant treatment differences in either males or females, for organ weights normalized by the brain weight. 
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Subchronic toxicity of StemEnhance™ in rats observed in animals that are not related to specific causes including age-related lesions, spontaneous lesions (including nonspecif ic genetic change), or environmentally induced lesions (infectious agents, feed, bedding, cleaning agents, etc). In all cases, there were no statistically significant differences in the distribution of the numbers and types of lesions between control and treated animals within the same gender or between genders (Table 3) . Thus, StemEnhance did not have a negative effect on any of the examined tissues.
hematology
The hematological findings in females (Table 4 ) and males (Table 5) did not show any consistent treatment-related effects. Values for some controls and some treated animals sporadically varied from the Charles River Laboratories reference range. There were no statistically significant differences in mean Hb, RBC, PCV, MCV, MCH, and MCHC values at any time points between the treated and control females and also between the treated and control males.
Mean WBC counts in all females and all males were within the reference range throughout the study. Mean WBC counts did not differ between groups at any time.
There were sporadic changes in neutrophil, lymphocyte, monocyte, and eosinophil counts in treated and control animals. Mean neutrophil, lymphocyte, monocyte, and eosinophil cell counts were within the reference ranges indicated for neutrophil (1%-32%), lymphocytes (67%-98%), 
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Dirikolu et al monocytes (0%-6%), and eosinophils (0%-3%) for females (Table 4 ) and males (Table 5 ) throughout the study.
clinical biochemistry
There were no consistent significant differences between treated and control animals in the serum analyses for females (Table 6 ) or males (Table 7) . Most means and individual concentrations in treated and control females were within the reference range throughout the study. The differences are described below. The mean ALT concentrations in treated and control females were within the reference range (23-67 U/L) (Table 6 ) before the dosing started. The mean ALT concentration for treated females (54.00 U/L), but not for control females (75.91 U/L), was within the reference range at the end of the dosing. Mean ALT concentrations in treated and control males were within the reference range (24-49 U/L) ( Table 7) before dosing started but not at the end of the dosing period (55.7 and 64.4 U/L, treated and control, respectively). The results of histopathological examination of the livers from animals that had high concentrations of ALT levels did not show any hepatic changes associated with subchronic hepatotoxic episode. 19 The mean calcium concentrations both in treated and control animals were not within the reference range for females (8.24-10 .36 mg/dL) ( Table 6 ) or males (8.08-9.92 mg/dL) ( Table 7 ) throughout the study. The mean phosphorus concentrations in treated and control females and males are shown in Tables 6 and 7 , respectively. There were no statistically significant differences in mean phosphorus or mean calcium concentrations between the treated and control females or between the treated and control males at any time points.
The mean potassium concentrations were within the reference range both in treated and control females (4.8-7.2 mmol/L) ( Table 6 ) and males (5.2-7.8 mmol/L) ( Table 7 ) throughout the study. The mean chloride concentrations were within the reference range in both treated and control females in comparison with the reference range for females (99-114 mmol/L) (Table 6 ) before the dosing started. Although the mean chloride concentration was within the reference range in control females, the mean in treated females (98.82 mmol/L) was slightly lower than 
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Subchronic toxicity of StemEnhance™ in rats the reference range after dosing. The mean chloride concentrations were slightly lower than the reference range (102-109 mmol/L) ( Table 7) in treated and control males throughout the study. There were no statistically significant differences in mean potassium or mean chloride concentrations between the treated and control females and also between the treated and control males at any time point. The mean sodium concentrations in the treated and control females were within the reference range (139-150 mmol/L) throughout the study (Table 6 ). The mean sodium concentrations were within the reference range both in treated and in control males at the end of the dosing period (Table 7) . There were no statistically significant differences in mean sodium concentrations between the treated and control females and also between the treated and control males at any time point. At the start of the study, chloride, potassium, and sodium were highly correlated in both groups, whereas at termination, there were no significant correlations among these constituents in either group.
The mean glucose concentrations were not within the reference range in control and treated females (Table 6 ) (85-132 mg/dL) and males (Table 7 ) (100-130 mg/dL) before and after dosing. Almost all the females and males in the treatment and control groups had glucose concentrations slightly above reference range throughout the study. There were no statistically significant differences in mean glucose concentrations between the treated and control females and also between the treated and control males at any time point.
All mean cholesterol concentrations were within the reference range for females (27.3-97.5 mg/dL) (Table 6 ) throughout the study and did not differ significantly at any time point. 
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Mean cholesterol concentrations at the end of the dosing period were within the reference range (42.9-78 mg/dL) in treated males but not in control males (86.75 mg/dL; Table 7 ). Administration of StemEnhance reduced the mean cholesterol concentrations in treated males and females in comparison to the predosing values, while in control males and females, the mean cholesterol concentration at the end of the dosing period was slightly above the predosing mean. Mean triglycerides concentrations in the treatment and control female groups were within the reference range (35.5-301.7 mg/dL) (Table 6 ) throughout the study. Although the mean triglycerides concentrations were within the reference range (35.5-186.3 mg/dL) 
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Subchronic toxicity of StemEnhance™ in rats in treated males at the end of the dosing period, the mean for the control males (220.3 g/dL) was above the reference range ( Table 7) . The mean triglycerides concentration at the end of the dosing period was significantly higher in treated females (133 g/dL) than in control females (113.7 g/dL), while the mean triglycerides concentration at the end of the dosing period was significantly lower in treated males (162.9 g/dL) than in control males (220.3 g/dL). The mean creatinine concentrations in treated and control females were below the reference ranges for female (0.42-0.60 mg/dL) (Table 6 ) throughout the study. Subsequently, the mean creatinine concentrations in treated and control males were below the reference ranges for male Wistar rats (0.35-0.55 mg/dL) ( Table 7 ). All the females and males in the treated and control groups had creatinine concentrations below the reference range throughout the study. The mean BUN concentrations in control and treated females were within the reference range (17-26 mg/dL) (Table 6 ) throughout the study. The mean BUN concentrations in control and treated males were within the reference range for males (16-23 mg/dL) ( Table 7 ) before dosing. After dosing, the mean BUN concentration for treated males was within the reference range, while the mean for control males (23.18 mg/ dL) was at the lower boundary. There were no statistically significant differences in mean BUN concentrations at any time points between the treated and control females and also between the treated and control males.
The mean globulin concentrations in treated and control animals were below the reference ranges for female (2.4-3.9 g/dL) ( Table 6 ) and male (2.5-3.8 g/dL) ( Table 7 ) Wistar rats at all times. The mean albumin concentrations in treated females were within the reference range (3.7-4.9 g/dL) ( Table 6 ) before dosing but not at the end of the dosing period. The mean albumin concentrations in treated and control males were within a reference range (3.3-4.7 g/dL) ( Table 7) before dosing and at the end of the dosing period. The mean total protein concentrations in the control and treatment groups were within the reference range for females (6.3-8.6 g/dL) ( Table 6 ) and males (6.5-7.8 g/dL) ( Table 7) at the end of the dosing period, but not before the dosing started. There were no statistically significant differences in mean total protein, mean globulin, or mean albumin concentrations between the treated and control females and also between the treated and control males at any time point.
Ki-67 ihc
The monoclonal antibody Ki-67 was used to show immunohistochemical expression of proliferating cells in the uterus. 12 The antibody reacts with a nuclear protein expressed in the G1, G2, S, and M phases of the cell cycle. Examination of uterine sections stained with Ki67 did not reveal any differences in females receiving StemEnhance compared to control animals.
epididymal sperm count and morphology
For the purposes of this report, we classify the sperm parameters as 'measured' and 'derived'. Table 8 Table 9 summarizes the morphological sperm analysis in both treated and control males.
Discussion and conclusion
Initially, there are some issues associated with the use of published 'normal' values that need to be addressed so that our results are properly interpreted. 'Normal' values are affected by the supplier, food, and housing conditions. As our predosing data show, the 'normal' values also vary within a 19 Occasionally, very small statistically significant differences occur between control and treated groups in toxicology studies, and unfortunately, the mechanism for the difference is usually not apparent.
Since the liver is the primary organ that detoxifies toxins, a liver function test is an important indicator of the safety of StemEnhance. Fostser and Wians provided a useful criterion of liver damage: increased serum levels of GGT in the presence of increased serum levels of ALP strongly suggest that the ALP originated from the liver. 22 Normal serum levels of GGT in the presence of increased serum levels of ALP, however, do not necessarily mean that the ALP originated from bone. At the end of the dosing period, for all animals, GGT concentrations were within the reference range, and we conclude from Wians's criterion that there is no evidence for liver damage or impaired liver function in any animal.
Another indicator of liver disease is the BUN-creatinine ratio. The ratio increases with renal disease but factors including liver function, dietary protein intake, and muscle mass can also affect results. Although BUN levels alone can increase with renal dysfunction, they also increase with dehydration and a high-protein diet. Creatinine does not increase with dehydration alone but definitely increases with renal dysfunction. For the controls, the BUN-creatinine ratios at 0 and 90 days were 81.2 ± 10.5 (61.7-97.0) and 82.3 ± 19.1 (49.0-121.5), respectively. For the animals receiving StemEnhance, the ratios were 87.7 ± 19.9 (55.0-121.4) and 100.5 ± 22.8 (64.0-135.0). At time 0, the variances did not differ between groups, whereas at 90 days, the variances were significantly different (control = 364.7, StemEnhance = 519.6), and the means differed significantly at 90 days but not at 0 day. However, most creatinine and BUN concentrations were within the reference range throughout the study, so taken together, there is no evidence of renal dysfunction.
In the subacute study, 9 there was a difference in sperm track speed (VCL), with a 10% reduction in the StemEnhance group relative to the controls. Extensive searching of the literature and discussions with experts failed to identify either a mechanism for this reduction or its clinical significance. In most published reports of adverse effects of chemicals on sperm motility, several motility parameters are affected in specific ways, and these patterns were not found for the treatment group rats. We speculated that the reduction in VCL was transitory and possibly related to the fact that the exposure/ postexposure observation period was almost exactly equal to the time span for meiosis in the Wistar rat. In light of this prior finding, the determination of whether or not sperm motility differs in rats following subchronic exposure to StemEnhance takes on special significance. As discussed above, except for a small difference in elongation, there were no differences in any of the measured or derived sperm motility parameters (Table 8) . Use of published reference values for sperm velocity measurements has to evaluate the equipment used, the computer processing, and instrument settings such as frame rate. Thus, for the same group of 30 sperm tracks of progressively motile human spermatozoa, the progression velocity (VSL) and VAP were approximately constant, but the VCL decreased as the sampling frequency decreased from 200 to 5 frames/sec. 23 Intra and interindividual variability have large coefficients 
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Subchronic toxicity of StemEnhance™ in rats of variation: in a workshop study of human sperm, the mean interindividual coefficients of variation were 22.9%, 21.8%, and 17.5% for sperm concentration, motility, and vitality, respectively. 24 For these and other reasons, toxic effects that affect sperm motility are evaluated in relation to changes that occur in particular patterns that involve both measured and derived parameters. 25 We conclude that StemEnhance had no toxic effects on sperm development or function based on the following: 1) none of the well-established patterns of toxicity affecting sperm are present in either the subacute or subchronic studies, 2) statistically significant differences in the sperm data are small changes in means, and 3) abnormal testicular histopathology is absent in the subacute 9 and subchronic studies.
Treatment-related morphological abnormalities were not found in any organs/tissues examined. These findings confirm that high-dose subchronic exposure to StemEnhance does not lead to toxicity. The dose of StemEnhance tested in the rat was ∼7 times higher than the maximum labelrecommended daily dose for human consumption. Therefore, it would appear that no toxicological hazard is likely due to the use of StemEnhance at label doses.
Nutrition and Dietary Supplements
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/nutrition-and-dietary-supplements-journal Nutrition and Dietary Supplements is an international, peer-reviewed, open access journal focusing on research into nutritional requirements in health and disease, impact on metabolism and the identification and optimal use of dietary strategies and supplements necessary for normal growth and development. The journal welcomes papers covering original research, basic science, clinical & epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. 
